Meaningful Outcomes for Longer, Healthier Lives

Arrivo is developing first-of-its-kind medicines for hard-to-treat diseases, targeting the diseases at their source to achieve meaningful outcomes for patients to live longer, healthier lives.

Read More

Meaningful Outcomes for Longer, Healthier Lives

Arrivo is developing first-of-its-kind medicines for hard-to-treat diseases, targeting the diseases at their source to achieve meaningful outcomes for patients to live longer, healthier lives.

Read More

Arrivo BioVentures

Arrivo BioVentures is the holding company for Sirtsei Pharmaceuticals, Inc. and Panafina Inc. Arrivo provides management oversite and funding for Sirtsei and Panafina.

Sirtsei

Pharmaceuticals, Inc.

Sirtsei holds the Intellectual Property for SP-624, a drug candidate initially being developed for major depressive disorder.

Panafina, Inc.

Panafina holds the Intellectual Property for RABI-767, a drug candidate in development for the treatment of patients predicted to advance to severe acute pancreatitis.

About Us

We are a team of experienced drug developers working in partnership with innovators, investors, and partners to develop first-of-its-kind medicines targeting the root cause of hard-to-treat diseases.

Learn More

Pipeline

Arrivo has two clinical-stage pipeline candidates, SP-624 for major depressive disorder and RABI-767 for predicted severe acute pancreatitis, each featuring new mechanisms of action.

Learn More

News

Feb.26.2025

Arrivo BioVentures’ SIRT6 Activator Receives United States Adopted…

Read More

Jan.10.2025

Arrivo BioVentures Announces Positive Results from qEEG…mm

Read More

Jan.03.2024

Psychiatry and Neuroscience Expert Dr. Joel Raskin Joins…kk

Read More